Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis

Digestion

Volumn 83, Issue 4, 2011, Pages 275-282

  Schütte, Kerstin ^a   Zimmermann, Lars ^a   Bornschein, Jan ^a   Csepregi, Antal ^a   Rühl, Ricarda ^a   Ricke, Jens ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Advanced hepatocellular carcinoma; Advanced liver cirrhosis; Sorafenib therapy

Indexed keywords

SORAFENIB;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79251552549     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320377     Document Type: Article

References (26)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750. (Pubitemid 29114292)
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763. (Pubitemid 351615415)
3. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917. (Pubitemid 37518510)
4. Lopez PM, Villanueva A, Llovet JM: Systematic review: evidence-based management of hepatocellular carcinoma - An updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-1547. (Pubitemid 43727460)
5. Bruix J, Boix L, Sala M, Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-219. (Pubitemid 38402113)
6. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al: Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004; 39: 1517-1524. (Pubitemid 38702652)
7. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858. (Pubitemid 46094197)
8. Gollob JA, Wilhelm S, Carter C, Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392-406. (Pubitemid 44142735)
9. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706-712. (Pubitemid 36528874)
10. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, et al: Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 2004; 29: 113-121. (Pubitemid 38667508)
11. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300. (Pubitemid 46630787)
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
13. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
14. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48:S20-S37.
15. Cabibbo G, Latteri F, Antonucci M, Craxi A: Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 159-169.
16. Llovet JM, Bruix J: Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 32: 679-680.
17. Llovet JM, Fuster J, Bruix J: The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004; 10:S115-S120. (Pubitemid 38240111)
18. Johnson PJ: Role of alpha-fetoprotein in the diagnosis and management of hepatcellular carcinoma. J Gastroenterol Hepatol 1999; 14(suppl):S32-S36. (Pubitemid 29281863)
19. Johnson PJ: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-159. (Pubitemid 32118643)
20. Chaparro M, Gonzalez Moreno L, Trapero- Marugan M, Medina J, Moreno-Otero R: Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008; 28: 1269-1277.
21. Zender L, Kubicka S: Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 2008; 550-555.
22. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, et al: Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? ASCO Meeting Abstracts 2008; 26: 4518.
23. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, et al: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76.
24. Wörns MA, Weinmann A, Pfingst K, Schulte- Sasse C, Messow CM, Schulze-Bergkamen H, et al: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495.
25. Chu D, Lacouture ME, Fillos T: Risk of handfoot skin reaction with sorafenib: a systemic review and meta-analysis. Acta Oncol 2008; 176-186.
26. Lacouture ME, Wu S, Robert C, Atkins MB, Ducher JP: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-1011.